Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Cash Flows

v3.23.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash Flows from Operating Activities:      
Net loss $ (28,634) $ (16,158) $ (16,829)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:      
Depreciation and amortization 497 400 499
Provision for bad debts 40 (202) 1,328
Provision for sales returns 0 0 87
Provision for inventory excess and obsolescence 1,312 (275) (591)
Inventory disposals and recoveries, net 1,486 (122) 1,300
Amortization of debt issuance costs 1,196 515 496
Patent litigation mark-to-market 0 315 0
Change in fair value of warrants 0 0 (5,850)
Issuance Of Restricted Shares 109 164 0
Issuance costs for common stock warrants 0 0 1,641
Stock-based compensation 2,303 1,662 3,370
Gain on debt forgiveness 0 (3,014) 0
Changes in operating assets and liabilities:      
Accounts receivable (1,643) (978) 4,286
Inventory (5,754) (1,375) 871
Prepaid expenses and other current assets (1,135) 285 825
Accounts payable and accrued liabilities 3,521 1,765 (2,107)
Deferred revenue (59) 308 (379)
Net cash and cash equivalents used in operating activities (26,761) (16,710) (12,795)
Cash Flows from Investing Activities:      
Purchases of property, plant, and equipment (3,727) (707) (96)
Net cash and cash equivalents used in investing activities (3,727) (707) (96)
Cash Flows from Financing Activities:      
Proceeds from the sale of common stock 5,602 14,420 6,912
Proceeds from the issuance of Series F Convertible Preferred Stock 0 0 2,700
Proceeds from the issuance of July 2020 Warrants 0 0 15,300
Payments of equity offering costs 0 (1,135) (1,281)
Payment of July 2020 Warrant issuance costs 0 0 (1,640)
Borrowings on other long-term loans 0 0 3,140
Principal payment on term loan (1,000) 0 (700)
Borrowings on credit facility 0 0 3,000
Payments of credit facility 0 0 (3,000)
Payments of debt issuance costs 0 (25) (128)
Proceeds from the exercise of common stock warrants 1 16,562 46
Proceeds from exercise of stock options 0 132 0
Net cash and cash equivalents provided by financing activities 4,603 29,954 24,349
Effect of exchange rate changes (109) (238) 317
Increase (decrease) in cash and cash equivalents (25,994) 12,299 11,775
Cash, cash equivalents and restricted cash, beginning of year 30,175 17,876 6,101
Cash, cash equivalents and restricted cash, end of year 4,181 30,175 17,876
Supplemental cash flow disclosure:      
Cash paid for interest 1,519 1,771 1,881
Cash received for interest 26 56 11
Cash paid for income taxes 59 171 22
Cash paid for operating leases 254 246 489
Non-cash settlement of liability 0 510 151
Non-cash right-of-use assets obtained in exchange for lease obligations 574 150 2,037
Equity financing costs in accounts payable 0 0 74
Deemed dividend on preferred stock 217 546 17,378
Forgiveness of debt 0 0 10
Receivable from warrants exercised and included in prepaid and other current assets 0 (1,498) 1,498
Warrants issued in connection with debt instruments $ 0 $ 0 $ 67